Inhibitory effect of clentiazem (TA-3090), a new calcium antagonist, on balloon catheter-induced intimal thickening of rabbit aorta.

abstract：:The DAVIT-II trial has shown that the verapamil type of calcium antagonist can beneficially be used in post-infarct patients. A recent re-analysis suggests that verapamil may also prevent post-infarct sudden death. There are good theoretical reasons to suppose that calcium antagonists should help prevent ventricular f...

journal_title：Cardiovascular drugs and therapy

authors： Opie LH

更新日期：1991-08-01 00:00:00

abstract：PURPOSE:The ischemic/bleeding trade-off of continuing dual antiplatelet therapy (DAPT) beyond 1 year after PCI for patients with high thrombotic risk (HTR) as endorsed by 2018 ESC/EACTS myocardial revascularization guidelines remain unknown. METHODS:Patients undergoing coronary stenting between January 2013 and Decemb...

journal_title：Cardiovascular drugs and therapy

authors： Wang HY,Dou KF,Wang Y,Yin D,Xu B,Gao RL

更新日期：2020-10-01 00:00:00

abstract：INTRODUCTION:Irisin is a newly identified 112 amino acid hormone, derived as a product of fibronectin type III domain containing 5 (FNDC5), which is highly related to metabolic activity in skeletal muscle and brown fat. The effects of irisin on cardiovascular functions are unknown. PURPOSE:To explore the effects of ce...

journal_title：Cardiovascular drugs and therapy

authors： Zhang W,Chang L,Zhang C,Zhang R,Li Z,Chai B,Li J,Chen E,Mulholland M

更新日期：2015-04-01 00:00:00

abstract：:In the latter half of the 20th century, among participants of the Framingham Heart Study, incidence of heart failure (HF) has declined by about a third in women but not in men and survival after the onset of HF has improved in both sexes; however, HF remains highly lethal with over 50% dying within 5 years after onset...

journal_title：Cardiovascular drugs and therapy

authors： Kenchaiah S,Vasan RS

更新日期：2015-08-01 00:00:00

abstract：BACKGROUND:Clinical guidelines recommend peri-cardioversion anticoagulation in patients with atrial fibrillation (AF). We performed a systematic review and meta-analysis to compare the safety and efficacy of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with AF undergoing cardiovers...

journal_title：Cardiovascular drugs and therapy

authors： Gupta S,Um KJ,Pandey A,McIntyre WF,Ivanova M,Allahverdi Y,Agahi P,Pandya F,Lopez A,Sachdeva A,Whitlock RP,Belley-Cote EP

更新日期：2019-06-01 00:00:00

abstract：:Angiotensin-converting enzyme (ACE) inhibitor therapy has been associated with a substantial (> or = 20%) reduction in the risk of major ischemic events in two recent clinical trials with long-term follow-up: Studies of Left Ventricular Dysfunction (SOLVD) and the Survival and Ventricular Enlargement (SAVE) study. Par...

journal_title：Cardiovascular drugs and therapy

authors： Young JB

更新日期：1995-02-01 00:00:00

abstract：PURPOSE:To compare the lifetime cost and effectiveness of five alternative chronic atrial fibrillation (AF) management strategies: rivaroxaban, warfarin, aspirin plus clopidogrel, aspirin and no prevention. METHODS:An individual-level state-transition model was developed to track the lifetime disease course associated...

journal_title：Cardiovascular drugs and therapy

authors： Wu B,Kun L,Liu X,He B

更新日期：2014-02-01 00:00:00

abstract：:The effects of administration of guava and papaya fruit (100 g/day), vegetables, and mustard oil (5 g/day) (group A); antioxidant vitamins C (50 mg/day) and E (30 mg/day), plus betacarotene (10 mg/day) (group B); a high-fat (5-10 g/day) (group C); or a low-fat (4-5 g/day) diet (group D) were compared over 24 diet week...

journal_title：Cardiovascular drugs and therapy

authors： Singh RB,Niaz AM,Ghosh S,Agarwal P,Ahmad S,Begum R,Onouchi Z,Kummerow FA

更新日期：1995-12-01 00:00:00

abstract：:Cilazapril, an angiotensin-converting enzyme inhibitor, and mibefradil, a selective T-type voltage-operated calcium channel blocker, have been shown to prevent neointima formation after vascular injury. The goal of the present study was to evaluate the mechanism of action of both drugs. For this purpose, the influence...

journal_title：Cardiovascular drugs and therapy

authors： Schmitt R,Clozel JP,Iberg N,Bühler FR

更新日期：1996-05-01 00:00:00

abstract：:In vitro and in vivo studies have demonstrated many similarities between the three calcium antagonists verapamil, nifedipine, and diltiazem in relation to protection of the myocardium during hypoxia. Important clinical differences exist between the three drugs when they are used during or after an acute myocardial inf...

journal_title：Cardiovascular drugs and therapy

authors： Hansen JF

更新日期：1991-08-01 00:00:00

abstract：:Patients with mild to moderate hypertension (diastolic blood pressure > or = 95 and < or = 115 mmHg) and renal dysfunction entered one of two studies to assess the safety of efficacious daily doses of quinapril on renal function and blood pressure. Twenty-four patients with moderate renal impairment (MRI) (creatinine ...

journal_title：Cardiovascular drugs and therapy

authors： Miller MA,Texter M,Gmerek A,Robbins J,Shurzinske L,Canter D

更新日期：1994-04-01 00:00:00

abstract：PURPOSE:A multicentre, randomized, double-blind, placebo-controlled, parallel-group study aimed to define the potential positive effect of dipeptidyl peptidase-4 inhibition on left ventricular systolic function (LVSF) beyond glycemic control in type 2 diabetes mellitus (T2DM) (DYDA 2™ trial). METHODS:Individuals with ...

journal_title：Cardiovascular drugs and therapy

authors： Giorda CB,Cioffi G,Lucci D,Nada E,Ognibeni F,Mancusi C,Latini R,Maggioni AP,DYDA 2 Investigators.

更新日期：2019-10-01 00:00:00

abstract：PURPOSE:The glucagon-like peptide-1 (GLP-1) has been shown to exert cardioprotective effects in animals and patients. This study tests the hypothesis that preservation of GLP-1 by the GLP-1 receptor agonist liraglutide or the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is associated with a reduction of angiote...

journal_title：Cardiovascular drugs and therapy

authors： Zhang LH,Pang XF,Bai F,Wang NP,Shah AI,McKallip RJ,Li XW,Wang X,Zhao ZQ

更新日期：2015-06-01 00:00:00

abstract：:Beta-blocker-induced benefit in heart failure is under intense evaluation. Several large-scale mortality trials are currently being performed, with CIBIS II evaluating bisoprolol. The economic impact of beta-blocker therapy in heart failure has not been previously determined. The present study is a cost-effectiveness ...

journal_title：Cardiovascular drugs and therapy

authors： Levy P,Lechat P,Leizorovicz A,Levy E

更新日期：1998-07-01 00:00:00

abstract：INTRODUCTION:Several beta blocking drugs (BB) reduce mortality in systolic heart failure (LVSD). We have compared the initial response to introduction of carvedilol and bisoprolol during the standard dose titration protocols for each drug. METHODS:Approximately 31 unselected patients with stable LVSD were randomised t...

journal_title：Cardiovascular drugs and therapy

authors： Hamaad A,Lip GY,Nicholls D,MacFadyen RJ

更新日期：2007-12-01 00:00:00

abstract：:When choosing antihypertensive agents for the treatment of hypertension, it is necessary to consider the predisposition of individuals to renal damage, which may be associated with the long-term effect of such agents. In this respect, this study examined the effect of two commonly used antihypertensive drugs (Brinerdi...

journal_title：Cardiovascular drugs and therapy

authors： Obatomi DK,Mogbo SC,Anjorin FI,Jigam AA

更新日期：1995-06-01 00:00:00

abstract：:Despite the fact that beta blockers were introduced into clinical practice 25 years ago, new beta blockers with differing kinetic and dynamic profiles continue to be developed and marketed. This overview assesses some of the more extensively studied agents from the point of view of proof of utility and the validity of...

journal_title：Cardiovascular drugs and therapy

authors： Fitzgerald JD

更新日期：1991-06-01 00:00:00

abstract：:Despite the impressive relation between an increased blood cholesterol and increased mortality from coronary artery disease and despite the persuasive results of cholesterol-lowering trials in secondary prevention, there are increasing reservations about the wisdom of lowering moderately raised blood cholesterol level...

journal_title：Cardiovascular drugs and therapy

authors： Opie LH

更新日期：1993-11-01 00:00:00

abstract：:The effects of nifedipine on left ventricular function were evaluated in 17 patients with coronary artery disease with an ambulatory radionuclide detector (VEST). Hemodynamic data were recorded continuously at rest and during upright bicycle ergometer exercise before and 30 minutes after 10 mg of oral nifedipine admin...

journal_title：Cardiovascular drugs and therapy

authors： Kambara H,Mohiuddin IH,Tamaki N,Fudo T,Hayashi M,Nohara R,Konishi J,Kawai C

更新日期：1990-08-01 00:00:00

abstract：:Eighteen hypertensive patients (13 males, 5 females; age 48 +/- 13; diastolic blood pressure greater than 95 mmHg), either previously untreated or who had been off treatment for more than 3 months, underwent M-mode echocardiography before (DO) and after (D90) 3 months of nicardipine therapy (60-90 mg/day). All echocar...

journal_title：Cardiovascular drugs and therapy

authors： Gosse P,Lacroix P,Roudaut R,Dallocchio M

更新日期：1989-08-01 00:00:00

abstract：:Based on a retrospective analysis of the DAVIT II database, we attempted to propose subgroups of post-infarction patients with heart failure, who might benefit or not benefit from antiischemic medical intervention. In DAVIT II, patients were randomized in a double-blind fashion to either verapamil 360 mg/day or placeb...

journal_title：Cardiovascular drugs and therapy

authors： Jespersen CM

更新日期：1994-12-01 00:00:00

abstract：PURPOSE:This study tested if the protective anti-remodeling effect of GLP-1 agonist Exendin-4 after an acute myocardial infarction (MI) in rats involves inhibition of the Wnt1/β-catenin signaling pathway. METHODS:Rats were divided into sham, sham + Exendin-4 (10 μg/day, i.p), MI, and MI + Exendin-4. MI was introduced ...

journal_title：Cardiovascular drugs and therapy

authors： Eid RA,Khalil MA,Alkhateeb MA,Eleawa SM,Zaki MSA,El-Kott AF,Al-Shraim M,El-Sayed F,Eldeen MA,Bin-Meferij MM,Awaji KME,Shatoor AS

更新日期：2020-05-30 00:00:00

abstract：:Major advances have been established in the handling of hypertensive vascular disease in recent years. However, drug compliance, drug costs, and the side effects of antihypertensive agents have prompted the question of whether intermittent therapy or even possible removal of medication represents an alternative to lif...

journal_title：Cardiovascular drugs and therapy

authors： Schmieder RE,Rockstroh JK

更新日期：1990-12-01 00:00:00

abstract：PURPOSE:Homocysteine (Hcy) is an independent risk factor for cardiovascular diseases that impairs endothelial function. We investigated whether the impaired endothelial function can be restored by the eNOS transcription enhancer AVE3085 in porcine coronary arteries. The effects of AVE3085 against Hcy on eNOS-NO functio...

journal_title：Cardiovascular drugs and therapy

authors： Yang Q,Xue HM,Underwood MJ,Yu CM

更新日期：2013-12-01 00:00:00

abstract：:Beneficial effects of monotherapy with ACE inhibitors or beta-blockers on hemodynamic function after myocardial infarction are well known. Until now, the effects of combined treatment on cardiac function and energy metabolism have been poorly described. This study examines the effects of combined ramipril and metoprol...

journal_title：Cardiovascular drugs and therapy

authors： Theres HP,Wagner KD,Romberg D,Feig C,Strube S,Leiterer KP,Günther J,Stangl K,Baumann G,Schimke I

更新日期：2000-12-01 00:00:00

abstract：PURPOSE:The benefits of statin treatment initiated in advanced age are largely unknown; however, good adherence to treatment is essential for beneficial effects to be achieved also when treating older people. This study characterizes older statin initiators, including their cardiovascular risk profiles and morbidity, a...

journal_title：Cardiovascular drugs and therapy

authors： Upmeier E,Korhonen MJ,Rikala M,Helin-Salmivaara A,Huupponen R

更新日期：2014-06-01 00:00:00

abstract：:We used Folts' model of critical coronary artery stenosis with endothelial damage, which measures platelet-rich thrombus accumulation from cyclic flow reductions (CFRs). This paper reports results applied to trimetazidine, a member of the piperazine group. Trimetazidine at a dose of 1 mg/kg completely abolished CFRs c...

journal_title：Cardiovascular drugs and therapy

authors： Belcher PR,Drake-Holland AJ,Hynd JW,Noble MI

更新日期：1993-02-01 00:00:00

abstract：:This review will present a summary of a description of apoptotic pathways in the heart, followed by ways to measure it and the experimental and clinical evidence for the role of apoptosis in cardiac disease. An evaluation of the effectiveness of pharmacological and other therapeutic interventions in the prevention of ...

journal_title：Cardiovascular drugs and therapy

authors： Neuss M,Crow MT,Chesley A,Lakatta EG

更新日期：2001-11-01 00:00:00

abstract：:This study compares the electrophysiologic effects of amlodipine and diltiazem in patients with coronary artery disease concomitantly treated with background beta-blocking therapy. Thirty patients were included in an open-label parallel study in two phases. During phase 1, patients were screened and placed on maintena...

journal_title：Cardiovascular drugs and therapy

authors： Santarelli P,Biscione F,Natale A,Manzoli A,Lanza GA

更新日期：1994-08-01 00:00:00

abstract：:Of 17 patients with mild to moderate essential hypertension, 8 showed echocardiographic evidence of left ventricular hypertrophy. Cardiac and renal function evaluated by glomerular filtration rate (GFR) were studied in all patients before and after 20 weeks of quinapril treatment. Systolic pressure decreased from 174....

journal_title：Cardiovascular drugs and therapy

authors： De Caprio L,De Rosa ML,Di Palma A,Lirato C,Caccese P,Sestito M,Lastoria S,Cicatiello AM,Rengo F

更新日期：1994-10-01 00:00:00